Research
Cellular
Tirzepatide may result in an increase in non-serious adverse events (risk ratio 1.33, 95% CI 1.03 to 1.71) compared to placebo.
Clinicians should monitor for non-serious adverse events when prescribing tirzepatide.
GoodQualifiesmedium confidence
Tirzepatide may result in an increase in non-serious adverse events (RR 1.33, 95% CI 1.03 to 1.71; 5 studies, 4582 participants; low-certainty evidence).
Why this rating
Based on randomized controlled trials with lower certainty.
Source
Tirzepatide for adults living with obesity
Juan Víctor Ariel Franco et al. · Cochrane Database of Systematic Reviews · 2025
DOI 10.1002/14651858.cd016018
Meta-analysisCited 3×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Tirzepatide likely results in a greater percentage reduction in body weight from baseline (mean difference -16.03, 95% CI -18.91 to -13.14) compared to placebo.Strong
- Tirzepatide likely increases the number of people achieving a 5% weight reduction (risk ratio 3.60, 95% CI 2.44 to 5.30) compared to placebo.Strong
Related findings · Cellular
- Athletes aiming to reduce fat mass and preserve FFM should consume protein intakes in the range of ∼1.8-2.7 g kg(-1) d(-1).Strong
- A minimum daily protein intake of ≥1.6 g/kg is necessary to observe significant improvements in muscle mass from whey protein supplementation.Strong
- Most athletes ideally need 1.2 to 2.0 grams/kg of body weight/day of protein, preferably split across 3-4 meals.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →